The Analyst Landscape: 4 Takes On Bio-Rad Laboratories
Portfolio Pulse from Benzinga Insights
Bio-Rad Laboratories (NYSE:BIO) has received mixed analyst ratings over the last three months, with a shift towards a more bullish stance in the last 30 days. The average 12-month price target is $412.5, a slight decrease from previous targets. Analyst actions include both upgrades and downgrades, reflecting dynamic market conditions and company performance. Bio-Rad, a leader in clinical diagnostics and life sciences, shows a lower market capitalization compared to industry averages, a -6.72% decline in revenue growth, but strong profitability indicators such as a net margin of 51.34% and high ROE and ROA. The company's financial health is solid, with a low debt-to-equity ratio.
May 08, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Rad Laboratories has seen a diverse range of analyst ratings, with a recent shift towards bullishness. The company's financials indicate challenges in revenue growth but strong profitability and financial health.
The shift towards more bullish analyst ratings and the setting of a new average 12-month price target, despite a slight decrease, indicate a positive outlook on BIO's stock. The company's strong profitability metrics and financial health, despite revenue challenges, suggest resilience and potential for growth, likely influencing a positive short-term impact on its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100